273 related articles for article (PubMed ID: 34008149)
1. Natural Killer Cells Recruitment in Oncolytic Virotherapy: A Mathematical Model.
Senekal NS; Mahasa KJ; Eladdadi A; de Pillis L; Ouifki R
Bull Math Biol; 2021 May; 83(7):75. PubMed ID: 34008149
[TBL] [Abstract][Full Text] [Related]
2. The two-faces of NK cells in oncolytic virotherapy.
Marotel M; Hasim MS; Hagerman A; Ardolino M
Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy.
Ghasemi M; Abbasi L; Ghanbari Naeini L; Kokabian P; Nameh Goshay Fard N; Givtaj N
Front Immunol; 2022; 13():950079. PubMed ID: 36703982
[TBL] [Abstract][Full Text] [Related]
4. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
[No Abstract] [Full Text] [Related]
5. Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment.
Aspirin AP; de Los Reyes V AA; Kim Y
J R Soc Interface; 2021 Jan; 18(174):20200669. PubMed ID: 33402021
[TBL] [Abstract][Full Text] [Related]
6. Role of NK cells in immunotherapy and virotherapy of solid tumors.
Cantoni C; Grauwet K; Pietra G; Parodi M; Mingari MC; De Maria A; Favoreel H; Vitale M
Immunotherapy; 2015; 7(8):861-82. PubMed ID: 26314197
[TBL] [Abstract][Full Text] [Related]
7. [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].
Kochneva GV; Sivolobova GF; Tkacheva AV; Gorchakov AA; Kulemzin SV
Mol Biol (Mosk); 2020; 54(1):3-16. PubMed ID: 32163385
[TBL] [Abstract][Full Text] [Related]
8. Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells.
Leung EYL; McNeish IA
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452316
[TBL] [Abstract][Full Text] [Related]
9. Cutting both ways: the innate immune response to oncolytic virotherapy.
Mealiea D; McCart JA
Cancer Gene Ther; 2022 Jun; 29(6):629-646. PubMed ID: 34453122
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy.
Ravirala D; Mistretta B; Gunaratne PH; Pei G; Zhao Z; Zhang X
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230110
[TBL] [Abstract][Full Text] [Related]
11. Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy.
Kim Y; Yoo JY; Lee TJ; Liu J; Yu J; Caligiuri MA; Kaur B; Friedman A
Proc Natl Acad Sci U S A; 2018 May; 115(19):4927-4932. PubMed ID: 29686060
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment?
Tassone E; Muscolini M; van Montfoort N; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():141-148. PubMed ID: 32859494
[TBL] [Abstract][Full Text] [Related]
13. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
Hofman L; Lawler SE; Lamfers MLM
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
[TBL] [Abstract][Full Text] [Related]
14. OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment.
Liu S; Li F; Ma Q; Du M; Wang H; Zhu Y; Deng L; Gao W; Wang C; Liu Y; Zhao Z; Liu H; Wang R; Tian Y; Hu M; Wan Y; Lu W; Zhang M; Zhao M; Cao Y; Zhang H; Wang W; Wang H; Wang Y
Theranostics; 2023; 13(12):4016-4029. PubMed ID: 37554264
[No Abstract] [Full Text] [Related]
15. The emerging field of oncolytic virus-based cancer immunotherapy.
Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach.
Mahasa KJ; Eladdadi A; de Pillis L; Ouifki R
PLoS One; 2017; 12(9):e0184347. PubMed ID: 28934210
[TBL] [Abstract][Full Text] [Related]
17. An Inter-Supplementary Biohybrid System Based on Natural Killer Cells for the Combinational Immunotherapy and Virotherapy of Cancer.
Ding L; Gao Q; Xu Z; Cai L; Chen S; Zhang X; Cao P; Chen G
Adv Sci (Weinh); 2022 Jan; 9(2):e2103470. PubMed ID: 34747156
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer.
van Vloten JP; Matuszewska K; Minow MAA; Minott JA; Santry LA; Pereira M; Stegelmeier AA; McAusland TM; Klafuric EM; Karimi K; Colasanti J; McFadden DG; Petrik JJ; Bridle BW; Wootton SK
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296558
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option.
Asija S; Chatterjee A; Goda JS; Yadav S; Chekuri G; Purwar R
Front Immunol; 2023; 14():1118246. PubMed ID: 37006286
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Metastatic Disease through Natural Killer Cell Modulation by Infected Cell Vaccines.
Niavarani SR; Lawson C; Tai LH
Viruses; 2019 May; 11(5):. PubMed ID: 31083491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
